Clinical outcomes
| Number of studies | Events/total (%) | Odds ratio (95% CI) | I2 heterogeneity | P value | ||
| FPE | Non-FPE | FPE vs non-FPE | ||||
| mRS score 0–2 at 90 days | 6 | 431/774 (56%) | 933/2285 (41%) | 1.78 (1.50 to 2.11) | 0 | <0.01 |
| sICH | 3 | 28/651 (4%) | 389/2118 (18%) | 0.41 (0.09 to 1.93) | 91 | 0.26 |
| Mortality | 5 | 129/771 (17%) | 610/2457 (25%) | 0.62 (0.50 to 0.76) | 0 | <0.01 |
| mFPE | Non-mFPE | mFPE vs non-mFPE | ||||
| mRS score 0–2 at 90 days | 7 | 339/591 (57%) | 402/917 (44%) | 1.73 (1.44 to 2.1) | 0.00 | <0.01 |
| sICH | 2 | 13/245 (5%) | 47/670 (7%) | 0.98 (0.51 to 1.88) | 0.00 | 0.95 |
| Mortality | 2 | 40/244 (16%) | 132/634 (21%) | 0.98 (0.66 to 1.49) | 0.00 | 0.95 |
FPE, first pass effect; mFPE, modified first pass effect; mRS, modified Rankin Scale; non-FPE, non-first pass effect; non-mFPE, non-modified first pass effect; sICH, symptomatic intracranial hemorrhage.